Gene study aims to personalize lung cancer chemotherapy

NCT ID NCT07145333

Ongoing Knowledge-focused Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how genetic differences (SNPs) in drug targets influence how well topotecan works and its side effects in 600 people with small cell lung cancer. Participants are randomly assigned to receive either the usual topotecan capsule or an imported version. Researchers will sequence specific genes to find links between genetics and treatment outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Topotecan
What this could lead to: If successful, this could help doctors predict which patients will benefit most from topotecan and who might have severe side effects, leading to more personalized treatment.
What could go wrong: This is an observational genetic analysis, not a test of a new treatment. The findings may not change current practice and require further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC

Contacts and locations

Locations

Medicine Invention Design Incorporation

Rockville, Maryland, 20853, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.